news

CUPERTINO, Calif., Sept. 17, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment for the trial consists of 12 severe patients (MELD 21-30) and 7 moderate patients (MELD 11-20) for a total of […]

CUPERTINO, Calif., Sept. 9, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER® technology has triggered a $10 million milestone payment from Gilead Sciences, Inc. to DURECT under the license agreement between the companies. “We are pleased that Gilead has been rapidly advancing

CUPERTINO, Calif., Sept. 4, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Monday, September 9, 2019 at 11:40 a.m. EDT.  Institutional

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Aug. 1, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update. Total revenues were $4.0 million and net loss was $7.2 million for the three months ended

CUPERTINO, Calif., July 25, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019. Thursday, August 1 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific TimeToll Free:                     877-407-0784International:               201-689-8560Conference

Gilead Also Receives Exclusive Option to License Additional Products for HIV and Hepatitis B CUPERTINO, Calif., July 22, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT’s SABER®

User Fee Goal Date is December 27, 2019 CUPERTINO, Calif., July 17, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT’s full response to the Complete Response Letter (CRL) it previously received from FDA related to POSIMIR® (bupivacaine extended-release solution) is

CUPERTINO, Calif., June 27, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration (FDA) related to POSIMIR® (bupivacaine extended-release solution).  The submission is intended to address the issues raised in the CRL and seeks

CUPERTINO, Calif., June 25, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 27, 2019. The Company has also

CUPERTINO, Calif., June 20, 2019 /PRNewswire/ — DURECT Corporation (“DURECT” or the “Company”) (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company agreed to sell and the investors agreed to purchase 29,000,000 shares of common stock